Press Releases
Press Releases
Sun Pharma Launches RIOMET ER Oral Suspension in the U.S.
Sun Pharmaceutical Industries Ltd. announced that one of its whollyowned subsidiaries has launched Riomet ER™ in the U.S. as an adjunct to diet and exercise to improve glycemic control in patients 10 years of age and older with type...
Press Releases
Dulaglutide Receives FDA Approval for Reducing MACE in Type 2 Diabetics
The U.S. FDA has approved Trulicity® (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple cardiovascular risk factors. This decision makes Eli Lilly and...
Clinical Trials
CytoDyn Receives IRB Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor Cancers
CytoDyn Inc , a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reported that it has received Institutional Review Board (IRB) approval to begin its Phase 2 clinical trial for...
IT & Data Management
SwRIs virtual screening software Rhodium increases processing power for coronavirus research
Drug discovery software at Southwest Research Institute is expanding the capacity to virtually screen drug compounds for possible treatment of coronavirus and other infectious diseases.
SwRI’s Rhodium™ virtual screening tool recently evaluated 2 million drug compounds in a few days,...
Press Releases
Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API)
Sanofi plans to create a major leading European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), which are the essential molecules responsible for the beneficial effects used in the composition of any...
Clinical Trials
Spring Bank Pharmaceuticals in Clinical Collaboration With Roche
Spring Bank Pharmaceuticals Inc. said it has entered into a new clinical collaboration with Roche to explore the co-administration of SB 11285, Spring Bank's intravenously-administered stimulator of interferon gene agonist with Roche's PD-L1 checkpoint inhibitor atezolizumab in patients with...
Drug Research
Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19
Vir Biotechnology, Inc. and WuXi Biologics announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of COVID-19 (Coronavirus Disease 2019), a disease caused by SARS-CoV-2.
Under the terms of the agreement, the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read